Skip to content

A Study of YVOIRE Y-Solution 360 for Hand Augmentation to Correct Volume Loss

A Multicenter, Randomized, No-treatment Controlled, Parallel, Evaluator-blind, Medical Device Pivotal Study to Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 360 Injected Into Dorsal Hand for Hand Augmentation to Correct Volume Loss

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04112017
Enrollment
116
Registered
2019-10-02
Start date
2019-09-27
Completion date
2020-10-14
Last updated
2021-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dorsal Hand Volume Loss

Keywords

Hyalunic acid, Filler, Dorsal hand, Medical device

Brief summary

The purpose of this study is to evaluate the effectiveness and safety of YVOIRE Y-Solution 360 in the treatment of dorsal hand to correct volume loss.

Interventions

Hyaluronic acid

Sponsors

LG Chem
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. 19 Years and older 2. Hand Volume Rating Scale (HVRS) of grade 2 or 3 with both hands 3. Participants who are willing to undergo the treatment of dorsal hand to correct volume loss

Exclusion criteria

1. Congenital defect, external injuries, lipodystrophy, unhealed wound, disease related-abnormalities, or tumors on the dorsal hands 2. Active inflammation or infection on the dorsal hands 3. Received anti-coagulation therapy, anti-platelet therapy, or expected to require repeated treatment within 2 weeks prior to visit 2 (randomization) 4. Had locally applied ointments (steroid, retinoid, anti-wrinkle production, tanning, or any other form of irritating product) or expected to require repeated treatment within 4 weeks prior to visit 2 (randomization) 5. Received immuno-suppressive medication including systemic glucocorticoids or expected to require repeated treatment within 8 weeks prior to visit 2 (randomization) 6. Received NSAIDs, Vitamin E, or expected to require repeated treatment within 1 week prior to visit 2 (randomization) 7. Had dermal filler injections (HA, CaHA, silicon, PAAG, PMMA etc.), Botulinum toxin therapy, adipose tissue transplantation, or esthetic surgery within 12 months prior to visit 2 (randomization)

Design outcomes

Primary

MeasureTime frameDescription
≥ 1 grade improvement on Hand Volume Rating Scale (HVRS) as assessed by the evaluator-blinded12 weeks after treatment5-grade photonumeric hand grading scale (grade 0 - grade 4)

Secondary

MeasureTime frameDescription
≥ 1 grade improvement on Hand Volume Rating Scale (HVRS) as assessed by the evaluator-blinded and the treating investigatorUp to 52 weeks after treatment5-grade photonumeric hand grading scale (grade 0 - grade 4)
≥ 1 grade improvement on Global Aesthetic Improvement Scale (GAIS) as assessed by the treating investigator and the subjectUp to 52 weeks after treatment5-point scale rating global aesthetic improvement in appearance (score -1 - score 3)
Change from baseline on Hand Volume Rating Scale (HVRS) as assessed by the evaluator-blinded and the treating investigatorUp to 52 weeks after treatment5-grade photonumeric hand grading scale (grade 0 - grade 4)
Change from baseline on Global Aesthetic Improvement Scale (GAIS) as assessed by the treating investigator and the subjectUp to 52 weeks after treatment5-point scale rating global aesthetic improvement in appearance (score -1 - score 3)
Safety profile as assessed by incidence of adverse eventsUp to 52 weeks after treatment

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026